Revance Therapeutics adopts amended bylaws aligning with SEC Rule 14a-19 on universal proxy

Revance Therapeutics, Inc.

Aligns director nomination and proxy solicitation with Rule 14a-19, requiring 67% voting power solicitation evidence.
Enhances disclosure requirements for nominating stockholders, nominees, and their associates and affiliates.
Removes references to California law and updates electronic notice provisions per Delaware DGCL changes.
Effective immediately as of December 12, 2023, following Board approval.
Includes immaterial modifications, conforming edits, and removal of loan-to-officers provision.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Revance Therapeutics, Inc.: Amended and Restated Bylaws to align with Rule 14a-19, enhance director nomination disclosures, and make other updates (effective 2023-12-12).

Change: bylaw amendment
Effective: 2023-12-12

Exact text from the filing

On December 12, 2023, in connection with the effectiveness of Rule 14a-19 ("Rule 14a-19") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), certain changes to the General Corporation Law of the State of Delaware (the "DGCL") and a periodic review of corporate governance matters, the board of directors (the "Board") of Revance Therapeutics, Inc. (the "Company"), approved and adopted the Amended and Restated Bylaws of the Company (as so amended and restated, the "Amended and Restated Bylaws"), effective immediately.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001479290-23-000114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.